[go: up one dir, main page]

TN2010000019A1 - Solid preparation comprising alogliptin and metformin hydrochloride - Google Patents

Solid preparation comprising alogliptin and metformin hydrochloride

Info

Publication number
TN2010000019A1
TN2010000019A1 TNP2010000019A TN2010000019A TN2010000019A1 TN 2010000019 A1 TN2010000019 A1 TN 2010000019A1 TN P2010000019 A TNP2010000019 A TN P2010000019A TN 2010000019 A TN2010000019 A TN 2010000019A TN 2010000019 A1 TN2010000019 A1 TN 2010000019A1
Authority
TN
Tunisia
Prior art keywords
metformin hydrochloride
solid preparation
alogliptin
salt
compound
Prior art date
Application number
TNP2010000019A
Other languages
English (en)
Inventor
Kazumichi Yamamoto
Hiroyoshi Koyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000019(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2010000019A1 publication Critical patent/TN2010000019A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2010000019A 2007-07-19 2010-01-11 Solid preparation comprising alogliptin and metformin hydrochloride TN2010000019A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007188574 2007-07-19
PCT/JP2008/063228 WO2009011451A1 (fr) 2007-07-19 2008-07-16 Preparation solide

Publications (1)

Publication Number Publication Date
TN2010000019A1 true TN2010000019A1 (en) 2011-09-26

Family

ID=39930391

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000019A TN2010000019A1 (en) 2007-07-19 2010-01-11 Solid preparation comprising alogliptin and metformin hydrochloride

Country Status (27)

Country Link
US (1) US8900638B2 (fr)
EP (1) EP2185138B1 (fr)
JP (2) JP5479318B2 (fr)
KR (1) KR101536786B1 (fr)
CN (1) CN101801351B (fr)
AR (1) AR067557A1 (fr)
AU (1) AU2008276842C9 (fr)
BR (1) BRPI0814299B8 (fr)
CA (1) CA2694620C (fr)
CO (1) CO6160301A2 (fr)
CR (1) CR11267A (fr)
DO (1) DOP2010000028A (fr)
EA (1) EA020870B1 (fr)
EC (1) ECSP109979A (fr)
ES (1) ES2603879T3 (fr)
GE (1) GEP20125672B (fr)
IL (1) IL203171A (fr)
JO (1) JO3272B1 (fr)
MA (1) MA31592B1 (fr)
MY (1) MY159203A (fr)
NZ (1) NZ583346A (fr)
PE (2) PE20090882A1 (fr)
TN (1) TN2010000019A1 (fr)
TW (1) TWI421102B (fr)
UA (1) UA98799C2 (fr)
WO (1) WO2009011451A1 (fr)
ZA (1) ZA201000831B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20090882A1 (es) * 2007-07-19 2009-08-03 Takeda Pharmaceutical Preparacion solida que comprende alogliptina y clorhidrato de metformina
EP2251005B1 (fr) * 2008-02-13 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Comprimés se délitant oralement
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX370599B (es) 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
AR073380A1 (es) * 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
AU2010228902A1 (en) 2009-03-26 2011-10-06 Mapi Pharma Limited Process for the preparation of alogliptin
ES2534312T3 (es) * 2009-05-13 2015-04-21 Wyeth Llc Procedimiento de estabilización de un suplemento dietético que comprende glucosamina
JP5784623B2 (ja) 2009-11-13 2015-09-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 速放性錠剤製剤
BR112012011726A2 (pt) 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
EP2504002B1 (fr) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Traitement de patients diabétiques génotypés par des inhibiteurs de dpp-iv tels que la linagliptine
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011141903A1 (fr) * 2010-05-12 2011-11-17 Mapi Pharma Holdings (Cyprus) Limited Polymorphes du benzoate d'alogliptine
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
JP2012051832A (ja) * 2010-08-31 2012-03-15 Fancl Corp 顆粒組成物及びそれを含有する食品又は医薬品
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2013077825A1 (fr) * 2011-11-23 2013-05-30 Mahmut Bilgic Procédé de fabrication d'une préparation comprenant de la metformine
EP4151218A1 (fr) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptine, dérivé de xanthine en tant qu'inhibiteur de dpp-4, destinée à être utilisée dans le traitement de sirs et/ou de sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CA2922849A1 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obesite, du diabete et de troubles associes
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
EP2769712A1 (fr) * 2013-02-21 2014-08-27 Siegfried International AG Formulation pharmaceutique comportant des agglomérats d'inhibiteur DPP-IV et des particules d'inhibiteur DPP-IV
CN103353491B (zh) * 2013-06-29 2018-11-16 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定苯甲酸阿格列汀原料及其制剂的方法
JP5922310B2 (ja) * 2013-07-25 2016-05-24 株式会社三和化学研究所 医薬製剤
CN104749269B (zh) * 2013-12-31 2018-12-28 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法
CN105527348B (zh) * 2014-09-28 2018-07-24 中美华世通生物医药科技（武汉）有限公司 分离分析苯甲酸阿格列汀制剂及其有关物质的方法
CN104569172A (zh) * 2014-11-05 2015-04-29 广东东阳光药业有限公司 一种用液相色谱检测苯甲酸阿格列汀片溶出度的方法
CN105675733B (zh) * 2014-11-17 2020-01-31 重庆医药工业研究院有限责任公司 一种用液相色谱法分离测定琥珀酸曲格列汀及其光学异构体的方法
PT3227204T (pt) * 2014-12-03 2020-03-26 Caffitaly System Spa Corpo de contenção para fabricar uma cápsula para preparar bebidas e método para fabricar cápsulas com diferentes quantidades de substância alimentar em pó utilizando um único tipo de corpo de contenção
CA2987850A1 (fr) 2015-06-17 2016-12-22 Hexal Aktiengesellschaft Formulation d'alogliptine
US10206923B2 (en) 2015-08-20 2019-02-19 Torrent Pharmaceuticals Limited Pharmaceutical composition of alogliptin and metformin
WO2017033115A1 (fr) * 2015-08-21 2017-03-02 Alembic Pharmaceuticals Limited Composition pharmaceutique stable d'une combinaison à dose fixée d'alogliptine et de metformine
AU2016343851B2 (en) * 2015-10-30 2022-04-07 Uswm, Llc Eflornithine and sulindac, fixed dose combination formulation
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN106008277A (zh) * 2016-06-12 2016-10-12 聊城大学 一种新型二甲双胍盐酸盐及其制备方法
CN106421794A (zh) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法
CN108318610A (zh) * 2017-12-29 2018-07-24 合肥拓锐生物科技有限公司 一种苯甲酸阿格列汀原料及其制剂中有关物质的分析方法
EP3784672A4 (fr) 2018-04-27 2022-03-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations de comprimés comprenant de la metformine et de la sitagliptine
CN108743611A (zh) * 2018-06-20 2018-11-06 常州制药厂有限公司 一种复方利血平片的制备方法
WO2020098904A1 (fr) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Forme posologique contenant de la metformine et un inhibiteur de la dipeptidyl peptidase iv
TR201907905A1 (tr) * 2019-05-24 2020-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Alogli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon
CN111537622B (zh) * 2019-11-29 2021-11-26 杭州华东医药集团新药研究院有限公司 一种度格列汀及其盐的杂质的检测方法
WO2023059118A1 (fr) * 2021-10-08 2023-04-13 (주)셀트리온 Composition pharmaceutique à stabilité améliorée pour le traitement du diabète sucré

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS49110814A (fr) * 1973-03-02 1974-10-22
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6803357B1 (en) 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
DK0974356T3 (da) 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
ITMI20002019A1 (it) 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
JP5183844B2 (ja) 1999-11-03 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー 糖尿病の治療方法
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
CA2408913A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US20050020671A1 (en) * 2001-02-14 2005-01-27 Matilde Fernandez Ibanez Pharmaceutical formulation
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
CA2452558C (fr) 2001-07-17 2009-12-22 N-Gene Research Laboratories Inc. Combinaison pharmaceutique synergique pour prevenir ou traiter le diabete
RU2004108219A (ru) 2001-09-28 2005-03-10 Сан Фармасьютикл Индастриз Лимитид (In) Лекарственная форма для лечения сахарного диабета
US20030187074A1 (en) 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
US20040125143A1 (en) 2002-07-22 2004-07-01 Kenneth Deaton Display system and method for displaying a multi-dimensional file visualizer and chooser
AU2003293311A1 (en) 2002-09-18 2004-04-23 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)
JPWO2004028524A1 (ja) 2002-09-26 2006-01-19 エーザイ株式会社 併用医薬
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1635832A2 (fr) 2003-06-06 2006-03-22 Merck & Co., Inc. Polytherapie permettant de traiter le diabete
CA2535619A1 (fr) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited Derives de 4-pyrimidone et leur utilisation en tant qu'inhibiteurs de la peptidyle peptidase
US7442720B2 (en) 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
KR100760430B1 (ko) 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
ES2445180T5 (es) * 2005-09-14 2022-02-01 Takeda Pharmaceuticals Co Administración de inhibidores de dipeptidil peptidasa
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
BRPI0620718A2 (pt) 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
WO2007078726A2 (fr) 2005-12-16 2007-07-12 Merck & Co., Inc. Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la métformine
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
RU2333760C2 (ru) 2006-05-16 2008-09-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Твердая дозированная лекарственная форма для лечения сахарного диабета
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CL2008000280A1 (es) * 2007-02-01 2008-08-18 Takeda Pharmaceutical Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y
ME01239B (me) * 2007-02-01 2013-06-20 Takeda Pharmaceuticals Co Čvrsti preparat koji sadrži alogliptin i pioglitazon
PE20090882A1 (es) * 2007-07-19 2009-08-03 Takeda Pharmaceutical Preparacion solida que comprende alogliptina y clorhidrato de metformina
RU2380097C1 (ru) 2009-01-20 2010-01-27 Общество с ограниченной ответственностью "ИТЭРА" Твердая дозированная лекарственная форма для лечения сахарного диабета

Also Published As

Publication number Publication date
AR067557A1 (es) 2009-10-14
JP2014058547A (ja) 2014-04-03
US20100136127A1 (en) 2010-06-03
CN101801351A (zh) 2010-08-11
US20110014299A2 (en) 2011-01-20
IL203171A (en) 2016-11-30
JP5479318B2 (ja) 2014-04-23
KR101536786B1 (ko) 2015-07-14
CA2694620A1 (fr) 2009-01-22
CO6160301A2 (es) 2010-05-20
NZ583346A (en) 2012-02-24
ZA201000831B (en) 2011-04-28
MY159203A (en) 2016-12-30
CR11267A (es) 2010-05-03
AU2008276842A1 (en) 2009-01-22
MA31592B1 (fr) 2010-08-02
UA98799C2 (ru) 2012-06-25
AU2008276842B2 (en) 2013-07-04
WO2009011451A1 (fr) 2009-01-22
KR20100036367A (ko) 2010-04-07
US8900638B2 (en) 2014-12-02
TW200914066A (en) 2009-04-01
PE20090882A1 (es) 2009-08-03
EP2185138A1 (fr) 2010-05-19
JP2010533643A (ja) 2010-10-28
PE20140923A1 (es) 2014-08-11
TWI421102B (zh) 2014-01-01
EP2185138B1 (fr) 2016-09-07
BRPI0814299A2 (pt) 2015-02-03
CN101801351B (zh) 2012-12-12
AU2008276842C1 (en) 2013-11-28
ES2603879T3 (es) 2017-03-01
CA2694620C (fr) 2016-05-31
BRPI0814299B1 (pt) 2018-12-18
EA020870B1 (ru) 2015-02-27
AU2008276842C9 (en) 2014-08-21
GEP20125672B (en) 2012-10-25
BRPI0814299B8 (pt) 2021-05-25
EA201070164A1 (ru) 2010-08-30
ECSP109979A (es) 2010-03-31
JO3272B1 (ar) 2018-09-16
DOP2010000028A (es) 2010-02-15

Similar Documents

Publication Publication Date Title
TN2010000019A1 (en) Solid preparation comprising alogliptin and metformin hydrochloride
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
WO2005075425A3 (fr) Derives de bisaryluree
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200833663A (en) Therapeutic agents
UA96449C2 (en) Stable laquinimod preparations
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
WO2005082414A3 (fr) Médicaments associés
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TNSN07419A1 (en) Methods for treating drug resistant cancer
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
WO2009060952A1 (fr) Nouvelle préparation
WO2007099171A3 (fr) Bicyclopyrazoles actifs comme inhibiteurs de la kinase
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200639156A (en) New compounds
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
TW200626158A (en) Naphthaline derivatives
WO2009050197A3 (fr) Composés organiques
TW200724539A (en) Benzimidazole derivative and use thereof
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
DK1791537T3 (da) 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase
JO2820B1 (en) Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases
WO2008098077A3 (fr) Composés thérapeutiques
WO2009017383A3 (fr) Formulation à libération prolongée comprenant un sel d'acide de metformine